Ftse Mib
34.490,71
0,07%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
69.178,56
0,95%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Jounce Therapeutics Inc (JNCE) Jounce Therapeutics Inc (JNCE) Notizie

JNCE

Jounce Therapeutics (JNCE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:JNCE
DataOraFonteTitoloSimboloCompagnia
14/02/202414:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JNCEJounce Therapeutics Inc
15/05/202313:41Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202322:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202322:35Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202312:09Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202314:40Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202313:31Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202313:25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202313:23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202313:08Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202302:35GlobeNewswire Inc.Jounce Therapeutics Announces Closing of Tender OfferNASDAQ:JNCEJounce Therapeutics Inc
28/04/202320:48Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:JNCEJounce Therapeutics Inc
03/04/202313:55Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:JNCEJounce Therapeutics Inc
03/04/202308:00GlobeNewswire Inc.Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plcNASDAQ:JNCEJounce Therapeutics Inc
27/03/202320:12Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:JNCEJounce Therapeutics Inc
27/03/202315:00GlobeNewswire Inc.Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value RightsNASDAQ:JNCEJounce Therapeutics Inc
16/03/202321:30GlobeNewswire Inc.Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerNASDAQ:JNCEJounce Therapeutics Inc
15/03/202302:00GlobeNewswire Inc.Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesNASDAQ:JNCEJounce Therapeutics Inc
14/03/202322:01Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:JNCEJounce Therapeutics Inc
10/03/202315:24Edgar (US Regulatory)Annual Report (10-k)NASDAQ:JNCEJounce Therapeutics Inc
06/03/202322:00Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:JNCEJounce Therapeutics Inc
23/02/202322:56Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:JNCEJounce Therapeutics Inc
23/02/202308:30GlobeNewswire Inc.Redx and Jounce Announce Recommended Business CombinationNASDAQ:JNCEJounce Therapeutics Inc
22/02/202323:00GlobeNewswire Inc.Jounce Therapeutics Announces RestructuringNASDAQ:JNCEJounce Therapeutics Inc
14/02/202322:55Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:JNCEJounce Therapeutics Inc
09/01/202312:02Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:JNCEJounce Therapeutics Inc
27/12/202223:24Dow Jones NewsGilead Sciences to Acquire Remaining Rights to GS-1811 from Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
27/12/202222:30Business WireGilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
27/12/202222:30GlobeNewswire Inc.Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
08/12/202213:50GlobeNewswire Inc.Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual CongressNASDAQ:JNCEJounce Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:JNCE

La tua Cronologia

ASX
KAINF
Kairos Minerals
CEGG
FILUSDT
Filecoin
BIT
F19036
Vontobel Financial Produ...
BIT
INFL10
Ubs Lux Fund Sol - Bbg B...
COIN
NBPETH
NFTBomb Protocol
TSX
ORE
Orezone Gold
LSE
30HL
Ang.w.s.f.3.070
AMEX
EWY
iShares MSCI South Korea...
BOV
CSRN-DEB720B
COSERN
LSE
SSLN
Ishs Silver �
BIT
F16144
Vontobel Financial Produ...
NASDAQ
LIFW
MSP Recovery
LATK
R1USDT
Recast1
EU
NGIAZ
GdF Suez SA Eo-med.-term...
BIT
I09841
IT0005574675 20240902 6.8
BIT
P1P5U1
BNP Paribas Issuance
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network